Alan D. Smith

Cancer immunotherapies targeting the PD-1 signaling pathway

Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy

LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation

Cardiovascular and musculoskeletal response to supervised exercise in patients with intermittent claudication

Measuring the multifaceted roles of mucin-domain glycoproteins in cancer

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

CCR9 in cancer: oncogenic role and therapeutic targeting

The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth

Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy

Direct and Indirect Modulation of T Cells by VEGF-A Counteracted by Anti-Angiogenic Treatment

Degradation from the outside in: Targeting extracellular and membrane proteins for degradation through the endolysosomal pathway

Induced protein degradation: an emerging drug discovery paradigm

Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy

Amplification of MUC1 in prostate cancer metastasis and CRPC development

Society for Vascular Surgery practice guidelines for atherosclerotic occlusive disease of the lower extremities: Management of asymptomatic disease and claudication

Drug discovery in advanced prostate cancer: translating biology into therapy

Strategies for modern biomarker and drug development in oncology

Novel drugs targeting the androgen receptor pathway in prostate cancer

A validated biomarker panel to identify peripheral artery disease

A phase 3 trial evaluating efficacy and safety of lenvatinib in combination with pembrolizumab in patients with advanced endometrial cancer.